TerrAscend Corp. Third Quarter 2026 Financial Results - TerrAscend Corp.

Explicit Guidance:

• Q4 2026 revenue growth expected at mid-single-digit year-over-year rates.
• Q4 2026 gross margins expected to remain consistent and strong.
• FY2027 outlook: Management projects a transformed business model and significant financial improvement compared to current operations.
• Share repurchase authorization active through August 23, 2027 (up to 10 million shares or $10 million).

Business-Segment Outlook:

• New Jersey: Planning ~20% increase in greenhouse yield at Boonton Cultivation Facility to support retail expansion and full brand portfolio; focus on accretive acquisitions and maximizing retail footprint; no material revenue impact from Aunt Mary's acquisition in Q3, with full run-rate ($10M+) expected moving forward.
• Maryland: Running at ~$75M annualized revenue with high-50s gross margins; focused on improving manufacturing efficiency and expanding footprint; gaining market share across flower, pre-rolls, vapes, and edibles.
• Pennsylvania: Facility operating at highest utilization in years; finished flower output up 68% YoY; prepared for adult use demand with current capacity sufficient to flex organically without additional CapEx; 16.8% total revenue growth driven by 12% same-store sales and 31% wholesale growth.
• Ohio: Double-digit revenue growth driven by consumer shift from unregulated hemp to regulated markets; actively evaluating disciplined, accretive acquisitions to build retail footprint.
• Product Portfolio: Continued launch of premium solventless, Legend brand (number 1 vape cartridge share), and Valhalla edibles; 100 mg medical trochies identified as a top-selling SKU in PA.

Market and Competitive Outlook:

• Regulatory Shift: Anticipated "return of consumers" to regulated markets following the December 11, 2026, intoxicating hemp ban; industry expected to double in size as consumers substitute illicit synthetic products with tested legal cannabis.
• Pricing & Demand: Pennsylvania retail prices increasing despite state-wide average price compression due to brand strength and product quality; Ohio seeing 20–30% revenue lift in stores impacted by hemp bans.
• Competition: Intense retail competition in NJ and PA, but TerraSense maintaining or gaining market share in most categories (vapes, flower, edibles) through vertical integration and brand loyalty.
• Market Structure: Medical cannabis rescheduling to Schedule 3 viewed as a "monumental inflection point" eliminating 280E tax burden, improving profitability, and lowering cost of capital.

Macro / Industry Outlook:

• 280E Tax Relief: Elimination expected to materially improve profitability and cash flow; potential for retroactive tax relief exists as a significant upside not currently priced in.
• Rescheduling Process: DEA inspections ongoing; management remains confident in the eventual rescheduling of cannabis (not just medical) despite uncertainty in timing.
• Interest Rates/Inflation: No explicit guidance provided, but focus on cost of capital improvement via 280E elimination.
• Regulatory Reform: Hemp regulation enforcement (intoxicating hemp ban) expected to drive market consolidation and revenue capture for licensed operators by December 2026.

Strategic Initiatives:

• M&A: Active pursuit of accretive acquisitions in core markets (NJ, MD, PA, OH) and new entry states (FL, MO); strategy targets distressed assets and multi-store deals; previously walked away from a PA deal due to discipline on price, signaling readiness for future transactions that fit financial criteria.
• Capacity Expansion: Boonton facility phase complete with ~20% yield increase; PA facility operating at peak utilization with excess capacity for adult use; no CapEx required for current PA growth ramp.
• Capital Allocation: Continued execution of share buyback program; balanced approach between M&A, growth investments, and CapEx.
• Uplisting: Active dialogue with major U.S. exchanges to prepare for potential listing on a U.S. exchange; steps being taken to meet requirements.
• Financing: No material debt maturities until 2028.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Timing and outcome of federal rescheduling remain uncertain; regulatory reform impacts may vary in magnitude.
• M&A Execution: Risk of failing to close accretive deals at appropriate valuations; past "swing and miss" in PA highlights the difficulty of pricing.
• Market Competition: Continued price compression and retail saturation in mature markets (NJ) could impact unit economics if vertical integration benefits do not fully offset.
• Execution Risk: New product launches and store openings carry integration risks; capacity constraints could limit growth if demand outpaces current facility output (though PA is currently non-constrained).
• Forward-Looking Statement Risks: Actual results may differ materially due to economic conditions, regulatory changes, and market dynamics.

Management Tone on the Future:

• Confidence Level: High confidence in future performance; explicit statement that the company "will look totally different in 2027."
• Strategic Focus: Shift from "being the biggest" to "being the best," prioritizing profitability and margin over pure top-line volume expansion.
• Discipline: Emphasis on "disciplined, accretive" capital allocation; willing to walk away from non-accretive deals.
• Sentiment: Optimistic regarding regulatory tailwinds (hemp ban, rescheduling) and the resulting market share capture from illicit channels.

Miscellaneous:

• Financial Metrics: 17 consecutive quarters of positive operating cash flow; 13 consecutive quarters of positive free cash flow; 17.7% operating cash flow yield and 14% free cash flow yield reported for Q3 2026.
• Debt Profile: Strong balance sheet with $42.5M cash and flexible term loan facility; no debt maturities until 2028.
• Brand Performance: Legend pre-rolls up 21% sequentially; Legend vapes hold 12.1% market share (1 of 215 brands); Flour rank #3 in NJ with 8.3% share.